CN105475569A - Preparation method of momordica grosvenori and adinandra nitida composite original tea - Google Patents
Preparation method of momordica grosvenori and adinandra nitida composite original tea Download PDFInfo
- Publication number
- CN105475569A CN105475569A CN201510973443.3A CN201510973443A CN105475569A CN 105475569 A CN105475569 A CN 105475569A CN 201510973443 A CN201510973443 A CN 201510973443A CN 105475569 A CN105475569 A CN 105475569A
- Authority
- CN
- China
- Prior art keywords
- tea
- momordica grosvenori
- preparation
- compound
- stone precipice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of momordica grosvenori and adinandra nitida composite original tea. The preparation method comprises the steps of mixing the momordica grosvenori and the adinandra nitida according to the weight ratio of (1 to 2) : (1 to 10), adding 60 to 75 v% of ethyl alcohol, extracting under an ultrasonic condition, concentrating an extracting solution, adding ethyl acetate for precipitation, performing suction filtration, taking the sediment for performing freeze drying, then the composite original tea is obtained. The composite original tea prepared by the invention not only has the synergistic effect of reducing blood glucose of diabetes, but also has a certain protective effect of improving diabetic complications of dyslipidemia and kidney injury.
Description
Technical field
The present invention relates to the preparation method of the former tea of a kind of compound, be specifically related to the preparation method of a kind of Momordica grosvenori and the former tea of stone precipice tea compound.
Background technology
Stone precipice tea (AdinandranitidaMerr.exH.L.Li), has another name called the dry leaf of Adinandra nitida, is rich in flavones, aldehydes matter, have the multiple biologically actives such as anti-oxidant, antibacterial, antitumor." the antioxidation activity research of Adinandra nitida " (is published in Southwestern University's M Sc thesis in May, 2013, Zhang Jingyi) after disclosing the ethanol extract of stone precipice tea being used benzinum, ethyl acetate, extracting n-butyl alcohol successively, petroleum ether extract, acetic acid ethyl ester extract, n-butyl alcohol extract is obtained respectively after Vacuum Concentration drying, after testing, in acetic acid ethyl ester extract flavones and polyphenol content the highest.According to similar dissolve mutually theory, flavones and polyphenol solubility in ethyl acetate is the highest, this illustrate in stone precipice tea active ingredient--the polarity connection of flavones and polyphenol is bordering on ethyl acetate.This paper is also pointed out further, three kinds of extracts are carried out external scavenging free radicals, the anti-oxidant measuring of HepG2 cell membrane to the Scavenging activity of external various free radical (as superoxide anion, hydroxyl radical free radical, DPPH, ABTS free radical etc.) and total reducing power, measure the Scavenging activity of each extract to HepG2 reactive oxygen species, found that the oxidation resistance of ethyl acetate is the strongest.Acetic acid ethyl ester extract is carried out growing animal experiment; result shows; acetic acid ethyl ester extract can improve mouse body enzymatic Antioxidative Defense System as the vigor of SOD, CAT; strengthen that self is anti-oxidant, the ability of scavenging free radicals; promote that the insulin cell of damage recovers, improve the physiological function of islet cells, realize the normalization of level of insulin secretion; reduce the diabetic mice fasting blood-glucose of STZ induction, and increase plasma insulin levels.This paper describes ethyl acetate effectively can extract flavones in the tea of stone precipice and polyphenol component, in acetic acid ethyl ester extract flavones and polyphenol content the highest, antioxidation activity and the blood sugar decreasing effect of acetic acid ethyl ester extract are best, and namely the content of stone precipice tea blood sugar decreasing effect and flavones and polyphenol is proportionate.
Momordica grosvenori (Siraitiagrosvenorii) is the distinctive plant in Guangxi, and its main component is Momordica-Glycosides, and sugariness is high, heat is low, lighter color, good water solubility, can be used as sweetener and replace sucrose, especially can be used as the substitute sugar of overweight people and diabetic.According to existing zoopery, Momordica-Glycosides can reduce mouse blood sugar.
Although prior art discloses stone precipice tea and Momordica grosvenori can be used for the treatment of diabetes separately, the target spot of its effect limits to relatively, effectively cannot prevent and treat the generation of diabetic complication.
Summary of the invention
The technical problem to be solved in the present invention is to provide the preparation method of a kind of Momordica grosvenori and the former tea of stone precipice tea compound; the former tea of this compound not only has synergy at diabetes blood sugar-reduction formula mask, and to improving diabetic complication Anomalous lipid metablism and kidney injury has certain protective effect.
Technical scheme provided by the invention is the preparation method of Momordica grosvenori and the former tea of stone precipice tea compound, Momordica grosvenori and stone precipice tea are mixed by 2 ~ 5:1 ~ 5 weight ratio, add the ethanol of 60 ~ 75v%, extract under Ultrasonic Conditions, extract is concentrated, adds ethyl acetate and precipitate, suction filtration, get pellet frozen drying, be the former tea of the former tea of compound.
Step 1) in, with volumetric concentration be 60 ~ 75% alcohol extract Momordica grosvenori and stone precipice tea in the active ingredient such as flavones, polyphenol and Momordica-Glycosides.The effect of ethyl acetate is to regulate polarity, and the component being insoluble to ethyl acetate is separated out.
When said extracted liquid carries out concentrated, be concentrated into 1/2 ~ 1/5 of extract original volume.Precipitate with the ethyl acetate of 2 ~ 3 times of concentrate volume.
Ultrasonic Conditions 1 ~ 3 time, each 1 ~ 2h; Ultrasonic Conditions is: temperature 40 ~ 50 DEG C, frequency are 250 ~ 400Hz.Preferred ultrasonic frequency is 300 ~ 400Hz.During each extraction, the addition of ethanol is 4 ~ 10 times of Momordica grosvenori and stone precipice tea gross weight.
The preferred weight ratio of Momordica grosvenori and stone precipice tea is 2:1.
Former tea of the present invention conveniently technique can be deployed into compound tea, for diabetes patients.
Compared with prior art; the present invention is extracted the component being insoluble to ethyl acetate in the ethanol extract of stone precipice tea and Momordica grosvenori; namely component akin with ethyl acetate polarity in ethanol extract is eliminated; by it in order to make the former tea of compound; not only there is good hypoglycemic effect, and to improving diabetic complication Anomalous lipid metablism and kidney injury has certain protective effect.
Detailed description of the invention
Embodiment 1
Momordica grosvenori and stone precipice tea are pressed 2:1 weight ratio co-grinding, add the ethanol of 60v%, the addition of ethanol is 4 times of Momordica grosvenori and stone precipice tea gross weight, 1h is extracted under being the Ultrasonic Conditions of 250Hz in temperature 40 DEG C, frequency, extract is concentrated into 1/2 of original volume, the ethyl acetate adding 2 times of concentrate volume precipitates, suction filtration, get pellet frozen drying, be the former tea of the former tea of compound.
Reference examples 1
Stone precipice tea is pulverized, add the ethanol of 60v%, 4 times of the addition stone precipice tea weight of ethanol, 1h is extracted under being the Ultrasonic Conditions of 250Hz in temperature 40 DEG C, frequency, extract is added ethyl acetate extract, get acetic acid ethyl ester extract reduced pressure concentration recycling design, freeze drying, be the former tea of stone precipice tea.
Reference examples 2
Momordica grosvenori is pulverized, adds the water of Momordica grosvenori weight 4 times, extract 1h in temperature 40 DEG C, frequency under being the Ultrasonic Conditions of 250Hz, extract is concentrated into medicinal extract, freeze drying, be the former tea of Momordica grosvenori.
Embodiment 2
Momordica grosvenori and stone precipice tea are pressed 1:1 weight ratio co-grinding, add the ethanol of 75v%, the addition of ethanol is 10 times of Momordica grosvenori and stone precipice tea gross weight, extracts 3 times, each 2h under temperature 50 C, frequency are the Ultrasonic Conditions of 400Hz, extract is merged, be concentrated into 1/5 of original volume, the ethyl acetate adding 3 times of concentrate volume precipitates, suction filtration, get pellet frozen drying, be the former tea of the former tea of compound.
Embodiment 3
Momordica grosvenori and stone precipice tea are pressed 5:1 weight ratio co-grinding, add the ethanol of 70v%, the addition of ethanol is 6 times of Momordica grosvenori and stone precipice tea gross weight, extracts 2 times, each 1.5h under temperature 45 C, frequency are the Ultrasonic Conditions of 300Hz, extract is merged, be concentrated into 1/3 of original volume, the ethyl acetate adding 2.5 times of concentrate volume precipitates, suction filtration, get pellet frozen drying, be the former tea of the former tea of compound.
Embodiment 4
Momordica grosvenori and stone precipice tea are pressed 2:5 weight ratio co-grinding, add the ethanol of 60v%, the addition of ethanol is 10 times of Momordica grosvenori and stone precipice tea gross weight, 2h is extracted under being the Ultrasonic Conditions of 400Hz in temperature 40 DEG C, frequency, extract is concentrated into 1/5 of original volume, the ethyl acetate adding 2 times of concentrate volume precipitates, suction filtration, get pellet frozen drying, be the former tea of the former tea of compound.
Experimental example
1, the foundation of diabetic mouse model
By the healthy kunming mice 100 of body weight at 18 ~ 22g, male and female half and half, carry out randomly drawing 20 after adaptability feeds one week for blank group, except blank group mouse feeds chow diet, all the other 80 mouse all feed high lipid food, feed equal overnight fasting after 4 weeks, take every Mouse Weight, and according to every Mouse Weight, give abdominal cavity, 80 mouse lower-lefts disposable injection Streptozotocin (STZ) the citric acid-sodium citrate parenteral solution 200mg/kg except blank group, blank group only injects the citric acid-sodium citrate buffer of equal volume.Inject after STZ3 days, fasting 12h, tail venous blood sampling surveys its fasting blood-glucose, and with fasting blood-glucose >=11.1mmol/L is the successful standard of experimental NIDDM Establishment of mouse model.
High lipid food is filled a prescription: basal feed 78.8%, yolk powder 10%, lard 10%, cholesterol 1%, sodium taurocholate 0.2%.
The mouse be successfully established by model is divided into model control group, experimental group, control group 1, control group 2 at random, often organizes 20.Model control group continues to give high lipid food, uses distilled water gavage.All the other each group while giving high lipid food, according to dosage 350mg/kg gives the former tea gavage of embodiment 1, reference examples 1 and reference examples 2 respectively.Every morning 9 gavages, every day 1 time, continuous gavage 12 weeks, fasting 12h after administration in 12nd week, to after every mouse according to dosage 2g/kg glucose gavage at the sugar tolerance that its corresponding time tail venous blood sampling measures, afterwards, weigh the body weight of every mouse, take to pluck eyeball method and get blood 1.5ml, upper serum is drawn after 3500r/min is centrifugal 10 minutes, pick the liver,spleen,kidney of mouse, pancreas, clean with physiological saline and weigh after blotting with clean filter paper to be placed on immediately in-80 DEG C of refrigerators together with serum and preserve, for subsequent use.
2, STZ is caused to the experiment of diabetic mice sugar tolerance
Gavage process is after 12 weeks, the equal fasting 8h of each group mouse, take mouse tail vein to get blood glucose value that blood records as the blood glucose value of 0h, then according to dosage 2g/kg gavage glucose solution, then after gavage 0.5,1,1.5,2h tail venous blood sampling measures blood glucose value.Observe the change of each group of blood sugar concentration on each time point.
3, the mensuration of indices
After diabetic mouse model is successfully established, every day observes the ordinary circumstance of mouse, as chroma of hair, motion frequency, feed inflow, body weight etc.Weigh the body weight of each group of mouse at gastric infusion in 12 weeks on every Fridays morning, and after fasting 12h, adopt tail venous blood sampling to measure the fasting blood sugar of each group of mouse.
3.1 blood preparation indexs
Go eyeball to get blood, the centrifugal 10min of 3500r/min, separation of serum, measure blood sugar (GLU), T-CHOL (TC), triglycerides (TG), serum creatinine (SCr) with full automatic biochemical apparatus; Glycosylated hemoglobin (GHbA1c), biological transforming factor β is measured with ELIASA
1(TGF-β
1).
3.2 urine specimen indexs
Experiment terminates the previous day collects 24h urine, gets 4ml after metering, and the centrifugal 10min of 3000r/min removes sediment, gets 2ml and measures 24h urine micro protein (mALB) and UCr (UCr).
4, experimental result:
The former tea of 4.1 compound causes the impact of diabetic mice fasting blood-glucose in table 1 to STZ:
The former tea of table 1 compound on STZ cause diabetic mice fasting blood-glucose impact (
n=20)
Note: each group compares with blank group, * p < 0.05, * * p < 0.01; Each group is compared with model control group, △ p < 0.05, △ △ p < 0.01.
The former tea of 4.2 compound causes the impact of diabetic mice sugar tolerance in table 2 to STZ:
The former tea of table 2 compound causes the impact of diabetic mice sugar tolerance on STZ
From table 1 and table 2, the former tea of experimental group has obvious hypoglycemic activity, improves its sugar tolerance, effectively have adjusted the glycometabolism in diabetic mice.
The former tea of 4.3 compound on STZ cause diabetic mice TC the impact of TG in table 3:
The former tea of table 3 compound on STZ cause diabetic mice TC TG impact (
n=20)
| Group | TC(mmol/l) | TG(mmol/l) |
| Blank group | 3.00±0.61△ | 1.15±0.33△ |
| Model control group | 4.72±3.22 | 1.36±0.72 |
| Experimental group | 3.70±1.43△ | 1.16±0.53△ |
| Control group 1 | 4.29±1.37△△ | 1.22±0.65△ |
| Control group 2 | 4.18±1.73△ | 1.24±0.85△ |
Note: administration is respectively organized after 12 weeks and compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 3, the former tea of compound of experimental group, by reducing cholesterol TC too high in diabetic mice, triacylglycerol TG, strengthen the ability of body lipid-metabolism, and successful is better than control group.
The former tea of 4.4 compound causes diabetic mice TGF-β to STZ
1, mALB, GHbA1c impact in table 4:
The former tea of table 4 compound causes diabetic mice TGF-β to STZ
1, mALB, GHbA1c impact (
n=20)
| Group | TGF-β 1(pg/ml) | mALB(μg/ml) | GHbA1c(ng/ml) |
| Blank group | 6.67±1.21△△ | 1.46±1.02△ | 4.77±1.09△ |
| Model control group | 17.11±1.30 | 19.91±3.61 | 13.77±1.02 |
| Experimental group | 7.28±1.04△ | 7.60±2.70△ | 5.65±1.80△△ |
| Control group 1 | 10.04±1.23△△ | 11.60±2.15△△ | 7.89±0.88△ |
| Control group 2 | 10.91±1.06△ | 10.60±2.70△ | 7.65±1.80△△ |
Note: administration is respectively organized after 12 weeks and compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 4, biological transforming factor β 1 is the important factor causing diabetic mice kidney injury, and the former tea of compound of experimental group can reduce the content of biological transforming factor β 1 in diabetic mice significantly, and effect is better than control group.Show that the kidney of experimental group to diabetic mice has protective effect, and certain prevention effect is played to the generation of diabetic nephropathy and development.
The former tea of compound of experimental group can obviously reduce glycated hemoglobin levels in Mice Body, alleviate because glycated hemoglobin levels raises the histanoxia caused to a great extent, alleviate glycated hemoglobin levels raise cause especially occur in the abundant position microangiopathies of kidney tip capilary, and then alleviate and cause histocyte hypoxic-ischemic and tissue damage thus, and then the content of microdose urine protein also significantly reduces.The former tea of compound of experimental group significantly can reduce the content of microdose urine protein and glycosylated hemoglobin in diabetic mice, have certain effect, and successful is better than control group to diabetes and nephropathy preventing.
The former tea of 4.5 compound causes the impact of diabetic mice serum creatinine (SCr) and UCr (UCr) in table 5 to STZ:
The former tea of table 5 compound on STZ cause diabetic mice serum creatinine (SCr) and UCr (UCr) impact (
n=20)
| Group | SCr(μmol/l) | UCr(μmol/l) |
| Blank group | 9.43±1.41△△ | 425.77±1.23△ |
| Model control group | 16.91±1.02* | 103.32±1.04** |
| Experimental group | 9.61±1.70**△△ | 221.78±1.20*△ |
| Control group 1 | 10.60±1.15*△ | 161.89±0.98*△△ |
| Control group 2 | 10.73±1.64**△△ | 158.65±1.36**△△ |
Note: administration is respectively organized after 12 weeks and compared with blank group, * p < 0.05, * * p < 0.01; Each group is compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 5, serum creatinine and UCr are all the indexs of reflection kidney injury degree.The former tea of experimental group compound can reduce the content of serum creatinine in diabetic mice significantly; and the content of UCr in diabetic mice can be improved significantly; concentration both the former tea of the former tea of illustrative experiment group compound can effectively regulate in diabetic mice; thus reach the effect of protection kidney, and successful is better than control group.
From table 1 ~ table 5, the former tea of compound of experimental group can by reducing cholesterol too high in diabetic mice, triacylglycerol, strengthen the ability of body lipid-metabolism, blood sugar level in remarkable reduction diabetic mice, improve its sugar tolerance, diabetic mice blood can also be improved simultaneously, the content of the UCr in urine, reduce diabetic mice blood, serum creatinine in urine, transforming growth factor-beta 1, microdose urine protein, effect of saccharification hemoglobin content, alleviate the kidney injury of diabetic nephropathy mouse, to the damage of prevention diabetic mice kidney, there is protective effect.
Claims (7)
1. the preparation method of Momordica grosvenori and the former tea of stone precipice tea compound, it is characterized in that: Momordica grosvenori and stone precipice tea are mixed by 2 ~ 5:1 ~ 5 weight ratio, add the ethanol of 60 ~ 75v%, extract under Ultrasonic Conditions, extract is concentrated, adds ethyl acetate and precipitate, suction filtration, get pellet frozen drying, be the former tea of compound.
2. the preparation method of Momordica grosvenori according to claim 1 and the former tea of stone precipice tea compound, is characterized in that: described concentrating is that extract is concentrated into 1/2 ~ 1/5 of original volume.
3. the preparation method of Momordica grosvenori according to claim 2 and the former tea of stone precipice tea compound, is characterized in that: the addition of described ethyl acetate is 2 ~ 3 times of concentrate volume.
4. the preparation method of Momordica grosvenori according to claim 1 and the former tea of stone precipice tea compound, is characterized in that: Ultrasonic Conditions 1 ~ 3 time, each 1 ~ 2h; Described Ultrasonic Conditions is: temperature 40 ~ 50 DEG C, frequency are 250 ~ 400Hz.
5. the preparation method of Momordica grosvenori according to claim 4 and the former tea of stone precipice tea compound, is characterized in that: described ultrasonic frequency is 300 ~ 400Hz.
6. the preparation method of the Momordica grosvenori according to any one of claim 1 ~ 6 and the former tea of stone precipice tea compound, is characterized in that: the addition of ethanol is 4 ~ 10 times of Momordica grosvenori and stone precipice tea gross weight.
7. the preparation method of the Momordica grosvenori according to any one of claim 1 ~ 6 and the former tea of stone precipice tea compound, is characterized in that: the weight ratio of Momordica grosvenori and stone precipice tea is 2:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510973443.3A CN105475569A (en) | 2015-12-22 | 2015-12-22 | Preparation method of momordica grosvenori and adinandra nitida composite original tea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510973443.3A CN105475569A (en) | 2015-12-22 | 2015-12-22 | Preparation method of momordica grosvenori and adinandra nitida composite original tea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105475569A true CN105475569A (en) | 2016-04-13 |
Family
ID=55663148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510973443.3A Pending CN105475569A (en) | 2015-12-22 | 2015-12-22 | Preparation method of momordica grosvenori and adinandra nitida composite original tea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105475569A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266626A (en) * | 2000-03-15 | 2000-09-20 | 黄志福 | Process for preparing clint tea bag |
| CN102218103A (en) * | 2011-06-16 | 2011-10-19 | 广西壮族自治区中医药研究院 | Application of extractive of adinandra nitida leaves to preparation of anti-inflammatory analgesia medicament |
| CN103272125A (en) * | 2013-06-22 | 2013-09-04 | 武汉久源生物医药科技有限公司 | Traditional Chinese medicine composition containing dendrobium huoshanense and having hypoglycemic effect, and preparation method thereof |
| CN103891952A (en) * | 2013-04-18 | 2014-07-02 | 王宗瑜 | Dendrobe and wallflower tea and preparation method thereof |
| CN104509921A (en) * | 2013-09-29 | 2015-04-15 | 桂林永福宏兴生物科技有限责任公司 | Fructus momordicae beverage preparation method |
| CN104585446A (en) * | 2015-02-06 | 2015-05-06 | 桂林双象生物科技有限公司 | Momordica grosvenori rock tea and preparation method for drink of momordica grosvenori rock tea |
| CN104587063A (en) * | 2015-02-06 | 2015-05-06 | 桂林双象生物科技有限公司 | Method for extracting total flavonoids from Adinandra nitida Merr.ex H.L.Li |
-
2015
- 2015-12-22 CN CN201510973443.3A patent/CN105475569A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266626A (en) * | 2000-03-15 | 2000-09-20 | 黄志福 | Process for preparing clint tea bag |
| CN102218103A (en) * | 2011-06-16 | 2011-10-19 | 广西壮族自治区中医药研究院 | Application of extractive of adinandra nitida leaves to preparation of anti-inflammatory analgesia medicament |
| CN103891952A (en) * | 2013-04-18 | 2014-07-02 | 王宗瑜 | Dendrobe and wallflower tea and preparation method thereof |
| CN103272125A (en) * | 2013-06-22 | 2013-09-04 | 武汉久源生物医药科技有限公司 | Traditional Chinese medicine composition containing dendrobium huoshanense and having hypoglycemic effect, and preparation method thereof |
| CN104509921A (en) * | 2013-09-29 | 2015-04-15 | 桂林永福宏兴生物科技有限责任公司 | Fructus momordicae beverage preparation method |
| CN104585446A (en) * | 2015-02-06 | 2015-05-06 | 桂林双象生物科技有限公司 | Momordica grosvenori rock tea and preparation method for drink of momordica grosvenori rock tea |
| CN104587063A (en) * | 2015-02-06 | 2015-05-06 | 桂林双象生物科技有限公司 | Method for extracting total flavonoids from Adinandra nitida Merr.ex H.L.Li |
Non-Patent Citations (2)
| Title |
|---|
| 唐慧勤等: "亮叶杨桐总黄酮对高脂血症大鼠脂代谢的影响及其抗氧化作用", 《中成药》 * |
| 杨祖金等: "超声波法强化提取罗汉果皂甙的工艺研究", 《中药材》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105381087A (en) | Preparation method of cyclocarya paliurus and Adinandra nitida Merr. ex H. L. Li compounded original tea | |
| CN109078042B (en) | Method for extracting active ingredients from radix puerariae through compound biological enzymolysis | |
| CN103103057A (en) | Preparation method of silkworm caterpillar fungus nutritive liqueur | |
| CN113546097B (en) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia | |
| CN102994305A (en) | Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon | |
| CN107412721A (en) | A kind of hypoglycemic bitter gourd polypeptide compound capsule and preparation method thereof | |
| CN102018751B (en) | Anti-hepatitis natural medicine compound preparation, preparation method and application thereof | |
| CN114632101A (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof | |
| CN111437310A (en) | Preparation method of high-activity oldenlandia diffusa total flavone and application of high-activity oldenlandia diffusa total flavone in liver peroxidation injury | |
| CN105412222A (en) | Preparation method of sweet tea and cyclocarya paliurus composite original tea | |
| CN103961534A (en) | Method for preparing cordyceps polysaccharide biological preparation | |
| CN105477370A (en) | Preparing method of sweet-dendrobe combined raw tea | |
| CN105412366A (en) | Making method of gynostemma pentaphyllum and shiya tea compounded crude tea | |
| CN102113993B (en) | Fine jade square and preparation method and application thereof | |
| CN102091117B (en) | Method for improving anticancer activity of Codonopsis lanceolata Benth.et Hook.F | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| CN105412367A (en) | Making method of compound raw tea of gingko and Adinandra nitida Merr.ex H.L.Li | |
| CN105475569A (en) | Preparation method of momordica grosvenori and adinandra nitida composite original tea | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN101926852A (en) | Application of roots and leaves of common fig in preparing auxiliary therapy medicine and health food for hepatitis | |
| CN105535036A (en) | A preparing method of rubus suavissimus-adinandra nitida leaf composite raw tea | |
| CN105535531A (en) | A preparing method of dendrobium-adinandra nitida leaf composite raw tea | |
| CN105535530A (en) | A preparing method of grosvenor momordica fruit-dendrobium-adinandra nitida leaf composite raw tea | |
| CN105535528A (en) | A preparing method of rubus suavissimus-dendrobium-adinandra nitida leaf composite raw tea | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160413 |